BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10.
BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion.
Revenue is projected to grow 123% this year and 79.63% next year, though earnings will dip 61.11% before rebounding 44.41%.
Despite bullish analyst sentiment, BBIO’s 12.3% short interest and volatility warrant caution.
Valued at $13.8 billion, BridgeBio Pharma (BBIO) discovers, develops and innovates drugs for genetic diseases. The company’s product platform consists of Mendelian, oncology and gene therapies. Its product pipeline includes BBP-265, BBP-831, and BBP-454 which are in clinical and preclinical stages.
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. BBIO checks those boxes. Since the Trend Seeker signaled a new “Buy” on Oct. 6, the stock has gained 29.85%.
www.barchart.com
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
BridgeBio hit an all-time high of $75.10 on Dec. 8.
BBIO has a Weighted Alpha of +168.02.
BridgeBio has a 100% “Buy” opinion from Barchart.
The stock gained 144.46% over the past year.
BBIO has its Trend Seeker “Buy” signal intact.
The stock recently traded at $70.96 with a 50-day moving average of $62.84.
BridgeBio made 12 new highs and gained 13.02% in the last month.
Relative Strength Index (RSI) is at 58.32.
There’s a technical support level around $70.52.
..
